We demonstrated that inhibition of G9a suppressed cellular proliferation and Wnt signaling pathway in NSCLC cells, suggesting overexpressed G9a represents a potential therapeutic target for NSCLC treatment. Here, EHMT2 is linked to non-small cell lung carcinoma.